Results 61 to 70 of about 166,333,307 (304)

An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report

, 2022
Background. Transformation of EGFR (epidermal growth factor receptor) - mutant non-small cell lung cancer (NSCLC) into small-cell lung cancer (SCLC) is one mechanism of resistance to tyrosine kinase inhibitor (TKI) treatment, seen in approximately 3-10 ...
Dalibor Ondrus, Peter Berzinec, Gabriela Kosturiakova, Monika Sekeresova, Lukas Plank, Gabriela Chowaniecova, Anna Farkasova, Dominik Juskanic   +7 more
core   +1 more source

Rab3B enhances the stabilization of DDX6 to promote lung adenocarcinoma aggressiveness

Molecular Medicine
Background Liver kinase B1 (LKB1) is frequently mutated in lung adenocarcinoma, and its loss contributes to tumor progression. Methods To identify LKB1 downstream genes that promote lung adenocarcinoma aggressiveness, we performed bioinformatical ...
Guodong Yao, Shan Yu, Feng Hou, Zunyu Xiao, Guangqi Li, Xiaobin Ji, Jigang Wang   +6 more
doaj   +1 more source

High-grade Fetal Adenocarcinoma of the Lung: A Case Report

Chinese Journal of Lung Cancer, 2019
Fetal adenocarcinoma of the lung (FLAC) is an extremely rare subtype of lung cancer, accounting for only 0.1% to 0.5% of primary pulmonary malignancy.
Chuan HUANG, Chao MA, Qingjun WU, Zheng WANG, Yaoguang SUN, Peng JIAO, Wenxin TIAN, Hanbo YU, Hongfeng TONG   +8 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

, 2017
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are associated with favorable response in EGFR mutant lung cancer.
Wu, Shang-Gin;Liu, Yi-Nan;Tsai, Meng-Feng;Chang, Yih-Leong;Yu, Chong-Jen;Yang, Pan-Chyr;Yang, James Chih-Hsin;Wen, Yueh-Feng;Shih, Jin-Yuan, 楊志新;張逸良;楊泮池;余忠仁;溫岳峰;吳尚俊;施金元   +1 more
core   +1 more source

Collision metastasis from prostate adenocarcinoma and pancreatic ductal adenocarcinoma to a lung nodule [PDF]

, 2023
Introduction Prostate cancer and pancreatic cancer are often complex pathologies that affect millions of patients worldwide. However, the incidence of a distant collision metastasis of both malignancies remains a rare and often poorly documented ...
Madaan, S., Saw, S., Mohamed, A., Clark, A., Yao, M.   +4 more
core   +1 more source

PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

Molecular Cancer, 2017
Background Protein regulator of cytokinesis-1 (PRC1) belongs to the microtubule-associated proteins (MAPs) family, and is involved in cytokinesis.
Ping Zhan, Bin Zhang, Guang-min Xi, Ying Wu, Hong-bing Liu, Ya-fang Liu, Wu-jian Xu, Qing-qing Zhu, Feng Cai, Ze-jun Zhou, Ying-ying Miu, Xiao-xia Wang, Jia-jia Jin, Qian Li, Li-ping Qian, Tang-feng Lv, Yong Song   +16 more
doaj   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients

, 2008
[[abstract]]Epidermal growth factor receptor (EGFR) plays an important role in the development and progression of a variety of malignant tumors. To test single nucleotide polymorphisms (SNPs) and haplotypes of the EGFR in modulating the lung cancer ...
Jou, YS;Lo, YL;Hsiao, CF;Chang, GC;Tsai, YH;Su, WC;Chen, YM;Huang, MS;Chen, HL;Chen, CJ;Yang, PC;Hsiung, CA
core   +2 more sources